Dr. Timothy Burns

Dr. Timothy Burns, of UPMC Hillman Cancer Center, discusses developments in the treatment of lung cancer over the next several years that have exciting potential to impact the field.

The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.